| Literature DB >> 29914292 |
Naji C Salloum1, Erica L F Buchalter1, Swati Chanani1, Gemma Espejo1, Mahjabeen S Ismail1, Randy O Laine2, Maysaa Nageeb1, A Benjamin Srivastava1, Nicholas Trapp1, Ludwig Trillo1, Erica Vance1, Michael Wenzinger1, Sarah M Hartz1, Sean P David3, Li-Shiun Chen1.
Abstract
Smoking cessation treatment outcomes may be heavily influenced by genetic variations among smokers. Therefore, identifying specific variants that affect response to different pharmacotherapies is of major interest to the field. In the current study, we systematically review all studies published in or after the year 1990 which examined one or more gene-drug interactions for smoking cessation treatment. Out of 644 citations, 46 articles met the inclusion criteria for the systematic review. We summarize evidence on several genetic polymorphisms (CHRNA5-A3-B4, CYP2A6, DBH, CHRNA4, COMT, DRD2, DRD4 and CYP2B6) and their potential moderating pharamacotherarpy effects on patient cessation efficacy rates. These findings are promising and call for further research to demonstrate the effectiveness of genetic testing in personalizing treatment decision-making and improving outcome.Entities:
Keywords: nicotine replacement therapy; pharmacogenetics; precision medicine; smoking cessation
Mesh：
Substances：
Year: 2018 PMID： 29914292 PMCID： PMC6219447 DOI： 10.2217/pgs-2018-0023
Source DB: PubMed Journal: Pharmacogenomics ISSN： 1462-2416 Impact factor: 2.533